Behnam Badie, M.D., Neurosurgeon and ...

Dr. Behnam Badie

Claim this profile

City of Hope Medical Center

Studies Glioblastoma
Studies Brain Tumor
6 reported clinical trials
9 drugs studied

Area of expertise

1

Glioblastoma

Behnam Badie has run 6 trials for Glioblastoma. Some of their research focus areas include:

Stage IV
IL13Rα2 positive
Stage III
2

Brain Tumor

Behnam Badie has run 4 trials for Brain Tumor. Some of their research focus areas include:

Stage IV
Stage III
IL13R alpha 2

Affiliated Hospitals

Image of trial facility.

City Of Hope Medical Center

Image of trial facility.

City Of Hope Comprehensive Cancer Center

Clinical Trials Behnam Badie is currently running

Image of trial facility.

CAR T-Cell Therapy

for Brain Tumor

This phase I trial tests the safety, side effects and best dose of TGFβR2KO/IL13Rα2 chimeric antigen receptor (CAR) T-cells given within the skull (intracranial) in treating patients with glioblastoma or IDH-mutant grade 3 or 4 astrocytoma that has come back after a period of improvement (recurrent) or that is growing, spreading, or getting worse (progressive). CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack tumor cells. T cells are taken from a patient's blood. When the cells are taken from the patient's own blood, it is known as autologous. Then the gene for special receptors that bind to a certain proteins on the patient's tumor cells are added to the T cells in the laboratory. The special receptors are called CAR. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain tumors. Giving TGFβR2KO/IL13Rα2 CAR T cells may be safe, tolerable, and/or effective in treating patients with recurrent or progressive glioblastoma or grade 3 or 4 IDH-mutant astrocytoma.

Recruiting

1 award

Phase 1

4 criteria

Image of trial facility.

CAR T-Cell Therapy + Immunotherapy

for Glioblastoma

This phase I trial studies the side effects and how well IL13Ralpha2-CAR T cells work when given alone or together with nivolumab and ipilimumab in treating patients with glioblastoma that has come back (recurrent) or does not respond to treatment (refractory). Biological therapies, such as IL13Ralpha2-CAR T cells, use substances made from living organisms that may attack specific glioma cells and stop them from growing or kill them. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving IL13Ralpha2-CAR T cells and nivolumab together may work better in treating patients with glioblastoma.

Recruiting

1 award

Phase 1

20 criteria

More about Behnam Badie

Clinical Trial Related

5 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Behnam Badie has experience with

  • IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells
  • Chimeric Antigen Receptor (CAR) T Cells With A Chlorotoxin Tumor-Targeting Domain
  • Ipilimumab
  • Nivolumab
  • IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes
  • HER2(EQ)BBζ/CD19t+ T Cells

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Behnam Badie specialize in?

Is Behnam Badie currently recruiting for clinical trials?

Are there any treatments that Behnam Badie has studied deeply?

What is the best way to schedule an appointment with Behnam Badie?

What is the office address of Behnam Badie?

Is there any support for travel costs?